578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy
نویسندگان
چکیده
منابع مشابه
Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Surgery, chemotherapy, and radiation therapy have been the foundation of cancer treatment. Advances in the field of immunology (a branch of science that studies all aspects of the immune system) have led to a greater understanding of the ways in which the body’s own defenses can be used for treatment of blood cancers. Cancer researchers are now studying how the immune system can help destroy ca...
متن کاملChimeric Antigen Receptor Engineered T (CAR-T) Cells and Cancer Therapy
Gene therapy has demonstrated significant potential as a cancer therapy in the last few years. The greatest successes have been reached by genetic modification of autologous patient T cells with chimeric antigen receptors (CARs), which are novel and synthetic receptors composed of the antigen-binding domain from a B cell receptor fused to the signaling elements associated with a T cell receptor...
متن کاملChimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have been shown to have unprecedented efficacy in B cell malignancies, most notably in B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate using anti-CD19 CAR-T cells. However, CAR T-cell therapy for solid tumors currently is faced with numerous challenges such as physical barriers, the immunosuppr...
متن کاملRegional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy
Chimeric Antigen Receptor (CAR) T-cells are T-cells with recombinant receptors targeted to tumor antigens. CAR-T cell therapy has emerged as a mode of immunotherapy and is now being extensively explored in hematologic cancer. In contrast, CAR-T cell use in solid tumors has been hampered by multiple obstacles. Several approaches have been taken to circumvent these obstacles, including the region...
متن کاملPD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.
Antibodiesblocking theprogrammeddeath1 receptor (PD-1) onTcells produce tumor regression in multiple cancers by disrupting the PD-L1/ PD-1 (programmed death-ligand 1/programmed cell death protein 1) immune inhibitory axis. This approach to cancer immunotherapy would seem to be an ideal partner for chimeric antigen receptor (CAR)– modified T-cell therapies but is, as yet, untested in this settin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Open Forum Infectious Diseases
سال: 2020
ISSN: 2328-8957
DOI: 10.1093/ofid/ofaa439.772